Medicine
Abacavir 300 mg tablet
Abacavir 300 mg tablet is a generic prescription medicine for oral use, made by 11 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Abacavir
- Brand
- Sold under the generic name
- Strength
- 300 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets, 50 blister pack, 1 bottle and 9 more
- Manufacturers
- Aurobindo PharmaIndiaCamber PharmaceuticalsIndiaCiplaIndiaMajor PharmaceuticalsAmerican Health PackagingAvPAKCouplerMylan InstitutionalMylan PharmaceuticalsSafecor Health
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AF06 Abacavir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 June 2012
- Identifiers
- RxCUI 242679DailyMed set ID 0d791375-e311-41f9-87b8-940657e6318c, 633f1ec9-53b1-4a9a-a738-8cae5b763f08, a2f06528-f3c5-2466-e053-2995a90ae18a +8NDC 69097-514, 72865-167, 50268-049 +8Application ANDA078119, ANDA091560, ANDA091294 +1
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, film coated in 1 bottle | 65862-073-60 | Aurobindo PharmaIndia | 17 December 2012 |
| 60 tablet in 1 bottle | 31722-557-60 | Camber PharmaceuticalsIndia | 1 April 2021 |
| 60 tablet, film coated in 1 bottle | 69097-514-03 | CiplaIndia | 21 November 2017 |
| 50 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 51079-204-06 | Mylan Institutional | 1 August 2012 |
| 1 bottle, plastic in 1 carton / 60 tablet, film coated in 1 bottle, plastic | 0378-4105-91 | Mylan Pharmaceuticals | 19 June 2012 |
| 60 tablet in 1 bottle | 72865-167-60 | XLCare Pharmaceuticals | 28 May 2021 |
| 30 blister pack in 1 box, unit-dose / 1 tablet, film coated in 1 blister pack | 68084-021-21 | American Health Packaging | 4 February 2013 |
| 20 blister pack in 1 box / 1 tablet in 1 blister pack | 50268-049-12 | AvPAK | 10 April 2020 |
| 30 tablet in 1 blister pack | 67046-1602-3 | Coupler | 1 April 2021 |
| 30 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0904-6874-04 | Major Pharmaceuticals | 17 December 2012 |
| 50 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0904-6874-06 | Major Pharmaceuticals | 17 December 2012 |
| 50 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 48433-001-06 | Safecor Health | 23 February 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Abacavir
Clinical summary
Abacavir is a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus (HIV-1) infection. It is available as tablets, oral solution and kits. MedsAcross supplies Abacavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AbacavirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZIAGEN prescribing information (ViiV Healthcare) · U.S. National Library of Medicine, DailyMed
- Ziagen: European public assessment report (EPAR) · European Medicines Agency
Need Abacavir 300 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.